New designer drug 2,5-dimethoxy-4-ethylthio-β-phenethylamine (2C-T-2): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry

Journal of Mass Spectrometry

Volumn 40, Issue 9, 2005, Pages 1157-1172

  Theobald, Denis S ^a   Staack, Roland F ^a   Puetz, Michael ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Bundeskriminalamt   (Germany)

Author keywords

2,5 dimethoxy 4 ethylthio phenethylamine; 2C T 2; GC MS; Metabolism; Urinalysis

Indexed keywords

ACETYLATION; ALCOHOLS; AMINES; BODY FLUIDS; DOSIMETRY; GAS CHROMATOGRAPHY; HYDROLYSIS; MASS SPECTROMETRY; METABOLISM; METABOLITES; OXIDATION; SOLVENT EXTRACTION; TOXIC MATERIALS;

2C-T-2; GC/MS; URIANALYSIS;

DRUG PRODUCTS;

2,5 DIMETHOXY 4 ETHYLTHIO BETA PHENETHYLAMINE; BENZOIC ACID DERIVATIVE; DESIGNER DRUG; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CONFERENCE PAPER; DEAMINATION; DEMETHYLATION; DOSE RESPONSE; DRUG ACETYLATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; GAS CHROMATOGRAPHY; HYDROLYSIS; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; REDUCTION; SULFATION; SULFOXIDATION; TOXICOLOGY; URINALYSIS;

ANIMALS; DESIGNER DRUGS; FORENSIC MEDICINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; PHENETHYLAMINES; RATS; RATS, WISTAR; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 25144434984     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.890     Document Type: Conference Paper

References (55)

1. Theobald DS, Staack RF, Maurer HH. New designer drug 2C-T-2: studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry (abstract). Ann. Toxicol. Anal. 2004; 16: 170.
2. de Boer D, Bosman I. A new trend in drugs-of-abuse; the 2C series of phenethylamine designer drugs. Pharm. World Sci. 2004; 26: 110.
3. Drug Enforcement Administration -Office of Forensic Sciences. Unusual polydrug seizure in Ellsworth, Kansas. Microgram 2004; 37: 8.
4. Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J. Anal. Toxicol 2003; 27: 493.
5. Drug Enforcement Administration - Department of Justice. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-Benzylpiperazine into schedule I of the controlled substances act. Fed. Register 2004; 69: 12794.
6. European Communities. Council decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2. Off. J. Eur. Commun. 2003; L321:64.
7. Theobald DS, Fehn S, Maurer HH. New designer drug, 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrum. 2005; 40: 105.
8. Johnson MP, Mathis CA, Shulgin AT, Hoffman AJ, Nichols DE. [125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav. 1990; 35: 211.
9. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 1992; 35: 734.
10. Glennon RA, Titeler M, Lyon RA. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol. Biochem. Behav. 1988; 30: 597.
11. Mon te AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 1996; 39: 2953.
12. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol. 2002; 136: 510.
13. Villalobos CA, Bull P, Saez P, Cassels BK, Huidobro-Toro JP. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 2004; 141: 1167.
14. Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J. Anal. Toxicol. 2004; 28: 407.
15. Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E, Veuthey JL, Kamalaprija P. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J. Anal. Toxicol. 1998; 22: 345.
16. Cole MD, Lea C, Oxley N. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci. Justice 2002; 42: 223.
17. de Boer D, Gijzels MJ, Bosman IJ, Maes RA. More data about the new psychoactive drug 2C-B [letter; comment]. J. Anal. Toxicol. 1999; 23: 227.
18. Bosman IJ, de Boer D, Siderius EB, Lesseps JALdR, Maes RAA. Mass spectrometric identification of some sulphur containing phenalkylamine designer drugs. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, Spiehler V (ed). TIAFT98: Albuquerque, 1999.
19. DeRuiter J, Clark CR, Noggle FT. LC and GC-MS analysis of 4-bromo-2,5-dimethoxyphenethylamine (Nexus) and 2-propanamine and 2-butanamine analogs. J. Chromatogr. Sci. 1995; 33: 583.
20. DeRuiter J, Clark CR, Noggle FT. Gas chromatographic-mass spectrometric and high-performance liquid Chromatographic analyses of the bromination products of the regioisomeric dimethoxyphenethylamines: differentiation of Nexus from five positional isomers. J. Chromatogr. Sci. 1998; 36: 23.
21. Ragan FA Jr, Hite SA, Samuels MS, Garey RE. 4-Bromo-2,5- dimethoxyphenethylamine: identification of a new street drug. J. Anal. Toxicol. 1985; 9: 91.
22. Chiu YC, Chou SH, Liu JT, Lin CH. The bioactivity of 2,5-dimethoxy-4- ethylthiophenethylamine (2C-T-2) and its detection in rat urine by capillary electrophoresis combined with an on-line sample concentration technique. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2004; 811: 127.
23. de Boer D, Lesseps JALdR, Gijzelsm M, Pilon N, Bosmanl J, Maes RAA. Studies on the metabolism of 2C-B. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, Spiehler V (ed). TIAFT98: Albuquerque, 1999.
24. Kanamori T, Inoue H, Iwata Y, Ohmae Y, Kishi T. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol. 2002; 26: 61.
25. Lin LC, Liu JT, Chou SH, Lin CH. Identification of 2,5-dimethoxy-4- ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2003; 798: 241.
26. Kanamori T, Tsujikawa K, Ohmae Y, Iwata Y, Inoue H, Inouye Y, Kishi T. Excretory profile of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rat. J. Health Sci. 2003; 49: 166.
27. Carmo H, Boer D, Remiao F, Carvalho F, Reys LA, Bastos ML. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2004; 811: 143.
28. Kanamori T, Tsujikawa K, Ohmae Y, Iwata YT, Inoue H, Kishi T, Nakahama T, Inouye Y. A study of the metabolism of methamphetamine and 4-bromo-2,5- dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forens. Sci. Int. 2005; 148: 131.
29. Maurer HH. Position of Chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control [review]. Clin. Chem. Lab. Med. 2004; 42: 1310.
30. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites, 4th ed. Agilent Technologies: Palo Alto, 2005.
31. Staack RF, Theobald DS, Maurer HH. Studies on the human metabolism and the toxicologic detection of the cough suppressant dropropizine in urine using gas chromatography-mass spectrometry. Ther. Drug Monit. 2004; 26: 441.
32. Staack RF, Maurer HH. Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2004; 804: 337.
33. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2004; 39: 255.
34. Paul LD, Maurer HH. Studies on the metabolism and toxicological detection of the Eschscholtzia californica alkaloids californine and protopine in urine using gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2003; 789: 43.
35. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 2003; 38: 971.
36. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J. Anal Toxicol. 2003; 27: 560.
37. Staack RF, Fehn J, Maurer HH. New designer drug paramethoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2003; 789: 27.
38. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2002; 773: 35.
39. Kraemer T, Bickeboeller-Friedrich J, Maurer HH. On the metabolism of the amphetamine-derived antispasmodic drug mebeverine: gas chromatography-mass spectrometry studies on rat liver microsomes and on human urine. Drug Metab. Dispos. 2000; 28: 339.
40. McLafferty FW, Turecek F. Interpretation of Mass Spectra, 4th ed. University Science Books: Mill Valley, 1993.
41. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. Wiley: New York, 1999.
42. Hubbard JW, Bailey K, Midha KK, Cooper JK. 3-O-methyl-alpha- methyldopamine, a urinary metabolite of p-methoxyamphetamine in dog and monkey. Drug Metab. Dispos. 1981; 9: 250.
43. Stack RF, Maurer HH. Metabolism of designer drugs of abuse [review]. Curr. Drug Metab. 2005; 6: 259.
44. Stack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH. Identification of human cytochrome p450 2D6 as major enzyme involved in the o-demethylation of the designer drug p-methoxymethamphetamine. Drug Metab. Dispos. 2004; 32: 379.
45. Charalampous KD, Walker KE, Kinross-Wright J. Metabolic fate of mescaline in man. Psychopharmacologia 1966; 9: 48.
46. Farber TM. Enzymatic S-de-ethylation and the mechanism of S-dealkylation. Proc. Soc. Exp. Biol. Med. 1975; 149: 13.
47. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J. Med. Chem. 1986; 29: 354.
48. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol. Pharmacol. 1983; 24: 471.
49. McBain JB, Menn JJ. S-methylation, oxidation, hydroxylation and conjugation of thiophenol in the rat. Biochem. Pharmacol. 1969; 18: 2282.
50. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 1996; 18: 465.
51. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [review]. Ther. Drug Monit. 2002; 24: 277.
52. Kovats E. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958; 41: 1915.
53. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG commission for clinical toxicological analysis, special issue of the TIAFT bulletin), 3rd ed. VCH Publishers: Weinheim, New York, Basel, 1992.
54. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.
55. Staack RF, Maurer HH. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2003; 798: 333.